Literature DB >> 7028904

A high-affinity binding site for the antioestrogens, tamoxifen and CI 628, in immature rat uterine cytosol which is distinct from the oestrogen receptor.

L C Murphy, R L Sutherland.   

Abstract

A high-affinity, saturable antioestrogen binding site, which does not bind oestradiol, has been reported to exist in a number of oestrogen target tissues but not in the immature rat uterus. This study reports the results of a more thorough search for this site in immature rat uterine cytosol. When concentrations of uterine cytoplasmic receptor were selectively depleted by translocation of 90-95% of the cytoplasmic oestrogen receptor to the nucleus, saturation analysis studies revealed that the antioestrogens, tamoxifen and CI 628, were bound to high-affinity, saturable binding sites which were present at about 2.5 times the concentration of the residual oestrogen receptor sites. Oestradiol could only partially inhibit the binding of tritiated antioestrogens to their saturable binding sites in this material indicating that a significant proportion of these sites were distinct from the oestrogen receptor sites. This was confirmed in experiments where oestrogen receptor sites were saturated in vitro with oestradiol and high-affinity, saturable sites for CI 628 and tamoxifen were still present. The CI 628 and tamoxifen had high affinity for these sites with dissociation constants of 1.0-1.6 nmol/l. These specific antioestrogen binding sites were present at about 5% of the concentration of oestrogen receptors in normal immature rat uterine cytosol which probably explains their previous lack of detections in this material.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028904     DOI: 10.1677/joe.0.0910155

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

1.  Changes in vascularization of human breast cancer xenografts responding to antiestrogen therapy.

Authors:  C A Kristensen; L M Hamberg; G J Hunter; S Roberge; D Kierstead; G L Wolf; R K Jain
Journal:  Neoplasia       Date:  1999-12       Impact factor: 5.715

2.  Microsomal binding sites for antioestrogens in rat liver. Properties and detergent solubilization.

Authors:  C K Watts; R L Sutherland
Journal:  Biochem J       Date:  1986-06-15       Impact factor: 3.857

Review 3.  Laboratory studies to develop general principles for the adjuvant treatment of breast cancer with antiestrogens: problems and potential for future clinical applications.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1983       Impact factor: 4.872

4.  ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.

Authors:  Joseph C Baker; Julie H Ostrander; Siya Lem; Gloria Broadwater; Gregory R Bean; Nicholas C D'Amato; Vanessa K Goldenberg; Craig Rowell; Catherine Ibarra-Drendall; Tracey Grant; Patrick G Pilie; Shauna N Vasilatos; Michelle M Troch; Victoria Scott; Lee G Wilke; Carolyn Paisie; Sarah M Rabiner; Alejandro Torres-Hernandez; Carola M Zalles; Victoria L Seewaldt
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-08       Impact factor: 4.254

5.  A study on the correlation between estrogen receptor, progesterone receptor and tamoxifen binding sites in human breast cancer tissues.

Authors:  Y Imanaka; S Tsuboi; N Kohno; Y Saitoh
Journal:  Jpn J Surg       Date:  1987-11

6.  Concentrations of tamoxifen and its major metabolites in hormone responsive and resistant breast tumours.

Authors:  J MacCallum; J Cummings; J M Dixon; W R Miller
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

7.  Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse.

Authors:  Y Iino; D M Wolf; S M Langan-Fahey; D A Johnson; M Ricchio; M E Thompson; V C Jordan
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.